JP2017502686A - 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 - Google Patents
発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 Download PDFInfo
- Publication number
- JP2017502686A JP2017502686A JP2016553231A JP2016553231A JP2017502686A JP 2017502686 A JP2017502686 A JP 2017502686A JP 2016553231 A JP2016553231 A JP 2016553231A JP 2016553231 A JP2016553231 A JP 2016553231A JP 2017502686 A JP2017502686 A JP 2017502686A
- Authority
- JP
- Japan
- Prior art keywords
- genbank accession
- accession number
- gene expression
- dlbcl
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 58
- 206010025323 Lymphomas Diseases 0.000 title claims description 42
- 238000010195 expression analysis Methods 0.000 title description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims abstract description 144
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims abstract description 142
- 230000014509 gene expression Effects 0.000 claims abstract description 142
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims abstract description 36
- 238000011282 treatment Methods 0.000 claims abstract description 32
- 238000001574 biopsy Methods 0.000 claims abstract description 26
- 210000001280 germinal center Anatomy 0.000 claims abstract description 13
- 208000003950 B-cell lymphoma Diseases 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 66
- 238000002560 therapeutic procedure Methods 0.000 claims description 29
- 238000003556 assay Methods 0.000 claims description 12
- 229960004641 rituximab Drugs 0.000 claims description 7
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 6
- 229960004397 cyclophosphamide Drugs 0.000 claims description 6
- 229960004528 vincristine Drugs 0.000 claims description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims description 5
- 101000701876 Homo sapiens Serpin A9 Proteins 0.000 claims description 5
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims description 5
- 102100030420 Serpin A9 Human genes 0.000 claims description 5
- 229960004679 doxorubicin Drugs 0.000 claims description 5
- 102100033900 Ankyrin repeat and SOCS box protein 13 Human genes 0.000 claims description 4
- 102100024133 Coiled-coil domain-containing protein 50 Human genes 0.000 claims description 4
- 102100039299 Cyclic AMP-responsive element-binding protein 3-like protein 2 Human genes 0.000 claims description 4
- 102100029713 E3 ubiquitin-protein ligase TRIM56 Human genes 0.000 claims description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 4
- 101000925512 Homo sapiens Ankyrin repeat and SOCS box protein 13 Proteins 0.000 claims description 4
- 101000910772 Homo sapiens Coiled-coil domain-containing protein 50 Proteins 0.000 claims description 4
- 101000745624 Homo sapiens Cyclic AMP-responsive element-binding protein 3-like protein 2 Proteins 0.000 claims description 4
- 101000795363 Homo sapiens E3 ubiquitin-protein ligase TRIM56 Proteins 0.000 claims description 4
- 101000852593 Homo sapiens Inositol-trisphosphate 3-kinase B Proteins 0.000 claims description 4
- 101001005101 Homo sapiens LIM domain-containing protein 1 Proteins 0.000 claims description 4
- 101001005668 Homo sapiens Mastermind-like protein 3 Proteins 0.000 claims description 4
- 101000593398 Homo sapiens Myb-related protein A Proteins 0.000 claims description 4
- 101000998596 Homo sapiens NADH-cytochrome b5 reductase 2 Proteins 0.000 claims description 4
- 101000609379 Homo sapiens Pre-mRNA-splicing factor ISY1 homolog Proteins 0.000 claims description 4
- 101000743768 Homo sapiens R3H domain-containing protein 1 Proteins 0.000 claims description 4
- 101001099877 Homo sapiens Ras-related protein Rab-43 Proteins 0.000 claims description 4
- 101000712725 Homo sapiens Ras-related protein Rab-7L1 Proteins 0.000 claims description 4
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 claims description 4
- 101000693262 Homo sapiens Sphingosine 1-phosphate receptor 2 Proteins 0.000 claims description 4
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims description 4
- 101000777156 Homo sapiens UBX domain-containing protein 4 Proteins 0.000 claims description 4
- 101000803751 Homo sapiens WD repeat-containing protein 55 Proteins 0.000 claims description 4
- 102100036404 Inositol-trisphosphate 3-kinase B Human genes 0.000 claims description 4
- 102100026033 LIM domain-containing protein 1 Human genes 0.000 claims description 4
- 102100025134 Mastermind-like protein 3 Human genes 0.000 claims description 4
- 102100034711 Myb-related protein A Human genes 0.000 claims description 4
- 102100033168 NADH-cytochrome b5 reductase 2 Human genes 0.000 claims description 4
- 102100038382 R3H domain-containing protein 1 Human genes 0.000 claims description 4
- 102100038479 Ras-related protein Rab-43 Human genes 0.000 claims description 4
- 102100033100 Ras-related protein Rab-7L1 Human genes 0.000 claims description 4
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 claims description 4
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 claims description 4
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims description 4
- 102100031308 UBX domain-containing protein 4 Human genes 0.000 claims description 4
- 102100035132 WD repeat-containing protein 55 Human genes 0.000 claims description 4
- 238000001959 radiotherapy Methods 0.000 claims description 4
- 238000011476 stem cell transplantation Methods 0.000 claims description 4
- 238000010322 bone marrow transplantation Methods 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 208000011691 Burkitt lymphomas Diseases 0.000 abstract description 36
- 210000001102 germinal center b cell Anatomy 0.000 description 63
- 239000000523 sample Substances 0.000 description 57
- 206010028980 Neoplasm Diseases 0.000 description 24
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 description 23
- 238000002493 microarray Methods 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 14
- 238000003500 gene array Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 238000011223 gene expression profiling Methods 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 101150098072 20 gene Proteins 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 7
- 238000003364 immunohistochemistry Methods 0.000 description 7
- 238000010200 validation analysis Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000001514 detection method Methods 0.000 description 4
- 201000003444 follicular lymphoma Diseases 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 238000010606 normalization Methods 0.000 description 4
- 238000003196 serial analysis of gene expression Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000011776 Aggressive B-cell non-Hodgkin lymphoma Diseases 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 238000002966 oligonucleotide array Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
- 201000003791 MALT lymphoma Diseases 0.000 description 2
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 238000003633 gene expression assay Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001744 histochemical effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003563 lymphoid tissue Anatomy 0.000 description 2
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 201000006039 nodal marginal zone lymphoma Diseases 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 1
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 206010003908 B-cell small lymphocytic lymphoma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 102100028122 Forkhead box protein P1 Human genes 0.000 description 1
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 1
- 101001059893 Homo sapiens Forkhead box protein P1 Proteins 0.000 description 1
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 description 1
- 101001111742 Homo sapiens Rhombotin-2 Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 102100023876 Rhombotin-2 Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 1
- 229960001507 ibrutinib Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 101150042836 mcl gene Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000008266 oncogenic mechanism Effects 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 239000005304 optical glass Substances 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011363 radioimmunotherapy Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
リンパ腫を同定及び分類するための様々なシステムが過去25年間にわたり提案されている。1980年代には、形態学的及び臨床的特徴に基づきリンパ腫を分類する方法としてWorking Formulationが導入された。1990年代には、リンパ腫を分類する際に免疫表現型的特徴及び遺伝的特徴を考慮に入れようと、Revised European-American Lymphoma(REAL)システムが導入された(Harris 1994)。世界保健機関(World Health Organization:WHO)により定められたごく最近のスタンダードは、これら従前のシステムに基づくよう試みられている(Swerdlow et al., eds., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed., International Agency for Research on Cancer;World Health Organization(2008);及びJaffe, E.S., Pathology & Genetics:Tumours of Haematopoietic and Lymphoid Tissues, WHO Classification of Tumours, Pathology and Genetics series(2001)を参照)。リンパ腫のWHO分類は、腫瘍の形態、免疫表現型、反復性遺伝子異常及び臨床的特徴を含むいくつかの因子に基づく。
本発明は、活性化B細胞様びまん性大細胞型B細胞リンパ腫(activated B cell-like diffuse large B cell lymphoma:ABC DLBCL)対象、胚中心B細胞様びまん性大細胞型B細胞リンパ腫(germinal center B cell-like diffuse large B cell lymphoma:GCB DLBCL)対象、縦隔原発B細胞リンパ腫(primary mediastinal B cell lymphoma:PMBL)対象、バーキットリンパ腫(Burkitt lymphoma:BL)対象、又はマントル細胞リンパ腫(mantle cell lymphoma:MCL)対象のために治療選択肢を選択するための方法を提供する。当該方法は以下を含む:(a)リンパ腫対象由来の生検サンプルから遺伝子発現産物を単離すること;(b)単離された遺伝子発現産物からデジタル遺伝子発現データを得ることであって、ここで、デジタル遺伝子発現データは、遺伝子発現シグネチャー(gene expression signature)における遺伝子についてのデータを含み、該遺伝子発現シグネチャーは、表2に列挙する遺伝子のうち少なくとも1つを含むものであること;(c)遺伝子発現シグネチャーからの遺伝子の加重平均発現レベルを作成し、それにより遺伝子発現シグネチャー値を得ること;(d)該遺伝子発現シグネチャー値に基づき予測スコア(predictor score)を算出すること;(e)(d)の予測スコアに基づき、以下のグループの1つに属するとして対象を分類すること:(i)ABC DLBCL、(ii)GCB DLBCL、(iii)PMBL、(iv)BL、又は(v)MCL;(f)(e)における対象の分類に基づき、該対象のために治療選択肢を選択すること;及び(g)該対象に該治療選択肢を提供すること。
癌細胞又は生検の遺伝子発現プロファイリングは、診断時における癌の分子表現型を反映する。結果として、ゲノム発現パターンにより提供される詳細な像は、新規な系統的癌分類についての根拠を提供し、生存率及び治療に対する反応性のより正確な予測因子を提供する。本発明は、リンパ腫、リンパ性悪性腫瘍又はリンパ増殖性障害をその遺伝子発現パターンに基づき同定、診断及び/又は分類するための方法を開示する。これらの方法を用いて得られた情報は、特定の対象に関して用いられるべき最適な治療アプローチを評価するのに有用であるだろう。
(1)MCLサブモデルが1の値を有する場合、サンプルはMCLとコールされる。
MCLサブモデルが0の値を有する場合、サンプルは、分類不能だがボーダーライン(unclassifiable but borderline)のMCLとコールされる。
MCLサブモデルが-1の値を有する場合、ステップ2に進む。
(2)BL non-mycサブモデルが1の値を有する場合、ステップ3に進む。
BL non-mycサブモデルが0の値を有する場合、サンプルは、分類不能だがボーダーラインのBLとコールされる。
BL non-mycサブモデルが-1の値を有する場合、ステップ4に進む。
(3)BL mycサブモデルが0又は1の値を有する場合、サンプルはBLとコールされる。
BL mycサブモデルが-1の値を有する場合、サンプルは、分類不能だがボーダーラインのBLとコールされる。
(4)PMBLサブモデルが1の値を有する場合、サンプルはPMBLとコールされる。
PMBLサブモデルが0の値を有する場合、サンプルは、分類不能だがボーダーラインのPMBLとコールされる。
PMBLサブモデルが-1の値を有する場合、ステップ5に進む。
(5)ABC/GCBサブモデルが1の値を有する場合、サンプルはABCとコールされる。
ABC/GCBサブモデルが0の値を有する場合、サンプルは未分類(unclassified)DLBCLとコールされる。
ABC/GCBサブモデルが-1の値を有する場合、サンプルはGCBとコールされる。
ABC/GCBサブモデルが1の値を有する場合、サンプルはABCとコールされる。
ABC/GCBサブモデルが0の値を有する場合、サンプルは未分類DLBCLとコールされる。
ABC/GCBサブモデルが-1の値を有する場合、サンプルはGCBとコールされる。
本実施例は、ホルマリン固定パラフィン包埋組織における遺伝子発現プロファイリングを用いて、びまん性大細胞型B細胞リンパ腫(DLBCL)のサブタイプを決定するための方法を実証する。
本実施例は、ホルマリン固定パラフィン包埋組織における遺伝子発現プロファイリングを用いて、侵攻性B細胞非ホジキンリンパ腫(agg-B-NHL)のサブタイプを決定するための方法を実証する。
Claims (8)
- 活性化B細胞様びまん性大細胞型B細胞リンパ腫(ABC DLBCL)対象、胚中心B細胞様びまん性大細胞型B細胞リンパ腫(GCB DLBCL)対象、縦隔原発B細胞リンパ腫(PMBL)対象、バーキットリンパ腫(BL)対象、又はマントル細胞リンパ腫(MCL)対象のために治療選択肢を選択するための方法であって、以下のステップ:
(a)リンパ腫対象由来の生検サンプルから遺伝子発現産物を単離すること;
(b)単離された遺伝子発現産物からデジタル遺伝子発現データを得ることであって、ここで、デジタル遺伝子発現データは、遺伝子発現シグネチャーにおける遺伝子についてのデータを含み、該遺伝子発現シグネチャーは、表2に列挙する遺伝子のうち少なくとも1つを含むものであること;
(c)遺伝子発現シグネチャーからの遺伝子の加重平均発現レベルを作成し、それにより遺伝子発現シグネチャー値を得ること;
(d)該遺伝子発現シグネチャー値に基づき予測スコアを算出すること;
(e)(d)の予測スコアに基づき、以下のグループの1つに属するとして対象を分類すること:(i)ABC DLBCL、(ii)GCB DLBCL、(iii)PMBL、(iv)BL、又は(v)MCL;
(f)(e)における対象の分類に基づき、該対象のために治療選択肢を選択すること;及び
(g)該対象に該治療選択肢を提供すること
を含む、方法。 - びまん性大細胞型B細胞リンパ腫(DLBCL)対象のために治療選択肢を選択するための方法であって、以下のステップ:
(a)DLBCL対象由来の生検サンプルから遺伝子発現産物を単離すること;
(b)単離された遺伝子発現産物からデジタル遺伝子発現データを得ることであって、ここで、デジタル遺伝子発現データは、遺伝子発現シグネチャーにおける遺伝子についてのデータを含み、該遺伝子発現シグネチャーは、以下の遺伝子のうち少なくとも1つを含むものであること:ASB13(GenBankアクセッション番号NM_024701.3)、CCDC50(GenBankアクセッション番号NM_174908.3)、CREB3L2(GenBankアクセッション番号NM_194071.2)、CYB5R2(GenBankアクセッション番号NM_016229.3)、IRF4(GenBankアクセッション番号NM_002460.1)、ISY1(GenBankアクセッション番号NM_020701.2)、ITPKB(GenBankアクセッション番号NM_002221.3)、LIMD1(GenBankアクセッション番号NM_014240.2)、MAML3(GenBankアクセッション番号NM_018717.4)、MME(GenBankアクセッション番号NM_000902.2)、MYBL1(GenBankアクセッション番号XM_034274.14)、PIM2(GenBankアクセッション番号NM_006875.2)、R3HDM1(GenBankアクセッション番号NM_015361.2)、RAB7L1(GenBankアクセッション番号NM_001135664.1)、S1PR2(GenBankアクセッション番号NM_004230.2)、SERPINA9(GenBankアクセッション番号NM_001042518.1)、TNFRSF13B(GenBankアクセッション番号NM_012452.2)、TRIM56(GenBankアクセッション番号NM_030961.1)、UBXN4(GenBankアクセッション番号NM_014607.3)、及びWDR55(GenBankアクセッション番号NM_017706.4);
(c)遺伝子発現シグネチャーからの遺伝子の加重平均発現レベルを作成し、それにより遺伝子発現シグネチャー値を得ること;
(d)該遺伝子発現シグネチャー値に基づき予測スコアを算出すること;
(e)(d)の予測スコアに基づき、以下のグループの1つに属するとして対象を分類すること:(i)活性化B細胞様びまん性大細胞型B細胞リンパ腫(ABC DLBCL)又は(ii)胚中心B細胞様びまん性大細胞型B細胞リンパ腫(GCB DLBCL);
(f)(e)における対象の分類に基づき、該対象のために治療選択肢を選択すること;並びに
(g)該対象に該治療選択肢を提供すること
を含む、方法。 - 治療選択肢が、以下:
CHOP療法、R-CHOP療法、CODOX-M/IVAC療法、R-EPOCH療法 CNS予防、放射線療法、免疫療法、骨髄移植、幹細胞移植、及び/又は手術
の1つ以上を含む、請求項1又は2に記載の方法。 - R-CHOP(リツキサン、シクロホスファミド、ヒドロキシダウノルビシン、オンコビン(ビンクリスチン)及びブレドニゾン)療法で治療するために、胚中心B細胞様びまん性大細胞型B細胞リンパ腫(GCB DLBCL)対象を選択するための方法であって、以下のステップ:
(a)DLBCL対象由来の生検サンプルから遺伝子発現産物を単離すること;
(b)単離された遺伝子発現産物からデジタル遺伝子発現データを得ることであって、ここで、デジタル遺伝子発現データは、遺伝子発現シグネチャーにおける遺伝子についてのデータを含み、該遺伝子発現シグネチャーは、以下の遺伝子のうち少なくとも1つを含むものであること:ASB13(GenBankアクセッション番号NM_024701.3)、CCDC50(GenBankアクセッション番号NM_174908.3)、CREB3L2(GenBankアクセッション番号NM_194071.2)、CYB5R2(GenBankアクセッション番号NM_016229.3)、IRF4(GenBankアクセッション番号NM_002460.1)、ISY1(GenBankアクセッション番号NM_020701.2)、ITPKB(GenBankアクセッション番号NM_002221.3)、LIMD1(GenBankアクセッション番号NM_014240.2)、MAML3(GenBankアクセッション番号NM_018717.4)、MME(GenBankアクセッション番号NM_000902.2)、MYBL1(GenBankアクセッション番号XM_034274.14)、PIM2(GenBankアクセッション番号NM_006875.2)、R3HDM1(GenBankアクセッション番号NM_015361.2)、RAB7L1(GenBankアクセッション番号NM_001135664.1)、S1PR2(GenBankアクセッション番号NM_004230.2)、SERPINA9(GenBankアクセッション番号NM_001042518.1)、TNFRSF13B(GenBankアクセッション番号NM_012452.2)、TRIM56(GenBankアクセッション番号NM_030961.1)、UBXN4(GenBankアクセッション番号NM_014607.3)、及びWDR55(GenBankアクセッション番号NM_017706.4);
(c)遺伝子発現シグネチャーからの遺伝子の加重平均発現レベルを作成し、それにより遺伝子発現シグネチャー値を得ること;
(d)該遺伝子発現シグネチャー値に基づき予測スコアを算出すること;
(e)(d)の予測スコアに基づき、以下のグループの1つに属するとして対象を分類すること:(i)活性化B細胞様びまん性大細胞型B細胞リンパ腫(ABC DLBCL)又は(ii)胚中心B細胞様びまん性大細胞型B細胞リンパ腫(GCB DLBCL);
(f)R-CHOP療法のために、GCB DLBCL対象を選択すること;並びに
(g)GCB DLBCL対象にR-CHOP療法を提供し、ABC DLBCL対象に異なる療法を提供すること
を含む、方法。 - ABC DLBCL対象に、CODOX-M/IVAC療法、R-EPOCH療法 CNS予防、放射線療法、免疫療法、骨髄移植、幹細胞移植、及び/又は手術を提供することを含む、請求項4に記載の方法。
- 遺伝子発現産物が、対象由来のホルマリン固定パラフィン包埋(FFPE)生検サンプルから単離される、請求項1〜6のいずれか一項に記載の方法。
- デジタル遺伝子発現データが、NANOSTRINGTMアッセイを用いて得られる、請求項1〜7のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361900553P | 2013-11-06 | 2013-11-06 | |
US61/900,553 | 2013-11-06 | ||
PCT/US2014/064161 WO2015069790A1 (en) | 2013-11-06 | 2014-11-05 | Method for subtyping lymphoma types by means expression profiling |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020018323A Division JP7016129B2 (ja) | 2013-11-06 | 2020-02-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2017502686A true JP2017502686A (ja) | 2017-01-26 |
JP2017502686A5 JP2017502686A5 (ja) | 2017-12-14 |
JP6657105B2 JP6657105B2 (ja) | 2020-03-04 |
Family
ID=51987470
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016553231A Active JP6657105B2 (ja) | 2013-11-06 | 2014-11-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
JP2020018323A Active JP7016129B2 (ja) | 2013-11-06 | 2020-02-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020018323A Active JP7016129B2 (ja) | 2013-11-06 | 2020-02-05 | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US10607717B2 (ja) |
EP (2) | EP3066215B1 (ja) |
JP (2) | JP6657105B2 (ja) |
KR (1) | KR102357699B1 (ja) |
CN (1) | CN106232831B (ja) |
AU (1) | AU2014346788B8 (ja) |
CA (1) | CA2929826C (ja) |
ES (2) | ES2738289T3 (ja) |
WO (1) | WO2015069790A1 (ja) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2736045C2 (ru) | 2015-03-06 | 2020-11-11 | Бейондспринг Фармасьютикалс, Инк. | Способ лечения рака, ассоциированного с мутацией ras |
US10609336B2 (en) * | 2015-04-16 | 2020-03-31 | Offender Smartphone Monitoring, LLC | Monitoring process |
WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
CA3000405A1 (en) | 2015-09-29 | 2017-04-06 | Htg Molecular Diagnostics, Inc. | Methods for subtyping diffuse large b-cell lymphoma (dlbcl) |
AU2017217426B2 (en) | 2016-02-08 | 2022-12-01 | Beyondspring Pharmaceuticals, Inc. | Compositions containing tucaresol or its analogs |
CA3021569A1 (en) | 2016-04-20 | 2017-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Evaluation of mantle cell lymphoma and methods related thereto |
EP3455368B1 (en) * | 2016-05-13 | 2023-11-29 | Roche Diagnostics GmbH | Methods and compositions for classifying dlbcl |
BR112018074990A2 (pt) | 2016-06-06 | 2019-03-12 | Beyondspring Pharmaceuticals, Inc. | composição, usos e método para reduzir neutropenia |
WO2018089442A2 (en) * | 2016-11-09 | 2018-05-17 | Intel IP Corporation | Ue and devices for detach handling |
CN110431135A (zh) | 2017-01-06 | 2019-11-08 | 大连万春布林医药有限公司 | 微管蛋白结合化合物及其治疗用途 |
US11400086B2 (en) | 2017-02-01 | 2022-08-02 | Beyondspring Pharmaceuticals, Inc. | Method of reducing chemotherapy-induced neutropenia |
EP3638814B8 (en) | 2017-06-14 | 2023-06-21 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Method for determining lymphoma type |
TWI772488B (zh) * | 2017-08-08 | 2022-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎DLBCL病患次族群之歐比托珠單抗(obinutuzumab)治療 |
EP3714271A1 (en) * | 2017-11-20 | 2020-09-30 | Julius-Maximilians-Universität Würzburg | Cd19cart cells eliminate myeloma cells that express very low levels of cd19 |
EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
CN110997919B (zh) | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
JP7436030B2 (ja) | 2017-12-29 | 2024-02-21 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 複合体及びその調製方法と使用 |
EP3743074A4 (en) | 2018-01-24 | 2021-12-15 | Beyondspring Pharmaceuticals Inc. | COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE |
CN112771178A (zh) * | 2018-08-01 | 2021-05-07 | 基因泰克公司 | Dlbcl起源细胞亚型的预测和表征 |
CN111655849B (zh) | 2018-08-21 | 2024-05-10 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的药物组合物和缀合物及其用途 |
CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
EP3867404A4 (en) * | 2018-10-15 | 2022-08-03 | Provincial Health Services Authority | GENE EXPRESSION PROFILES FOR B-CELL LYMPHOMAS AND THEIR USES |
JP2022513038A (ja) * | 2018-11-14 | 2022-02-07 | ビヨンドスプリング ファーマシューティカルズ,インコーポレイテッド | チューブリン結合薬を使用する癌の治療方法 |
CA3131874A1 (en) * | 2019-03-28 | 2020-10-01 | Philippe RUMINY | Classification of b-cell non-hodgkin lymphomas |
CN111850114A (zh) * | 2019-04-25 | 2020-10-30 | 上海交通大学医学院附属瑞金医院 | 一组用于评估弥漫大b细胞淋巴瘤分子分型的基因群,其试剂盒及分析方法 |
JP2022533419A (ja) * | 2019-05-22 | 2022-07-22 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
EP4013494A1 (en) | 2019-08-12 | 2022-06-22 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (mst1r) variants and uses thereof |
CN111621565B (zh) * | 2020-05-07 | 2023-12-15 | 杭州可帮基因科技有限公司 | 弥漫性大b细胞淋巴瘤分子分型试剂盒及分型装置 |
CN111785370B (zh) * | 2020-07-01 | 2024-05-17 | 医渡云(北京)技术有限公司 | 病历数据处理方法及装置、计算机存储介质、电子设备 |
BR112023000125A2 (pt) * | 2020-07-08 | 2023-04-11 | Dayton Therapeutics Ag | Satraplatina para uso no tratamento de neoplasias linfoides |
CN113186289B (zh) * | 2021-05-12 | 2023-02-24 | 清华大学深圳国际研究生院 | lncRNA在肾癌尿液筛查和肾癌治疗中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005024043A2 (en) * | 2003-09-03 | 2005-03-17 | Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
WO2008013910A2 (en) * | 2006-07-25 | 2008-01-31 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
WO2009149359A2 (en) * | 2008-06-06 | 2009-12-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Survival predictor for diffuse large b cell lymphoma |
JP2011510663A (ja) * | 2008-02-01 | 2011-04-07 | ザ ジェネラル ホスピタル コーポレイション | 医学的疾患および医学的状態の診断、予後および治療におけるマイクロベシクルの使用 |
WO2012149299A2 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
JP2012533308A (ja) * | 2009-07-16 | 2012-12-27 | ザ ジェネラル ホスピタル コーポレイション | 核酸分析 |
WO2013120086A1 (en) * | 2012-02-10 | 2013-08-15 | Whitehead Institute For Biomedical Research | Inhibition of the glycine cleavage system for treatment of cancer |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5242974A (en) | 1991-11-22 | 1993-09-07 | Affymax Technologies N.V. | Polymer reversal on solid surfaces |
US5800992A (en) | 1989-06-07 | 1998-09-01 | Fodor; Stephen P.A. | Method of detecting nucleic acids |
US5424186A (en) | 1989-06-07 | 1995-06-13 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
US6040138A (en) | 1995-09-15 | 2000-03-21 | Affymetrix, Inc. | Expression monitoring by hybridization to high density oligonucleotide arrays |
US5252743A (en) | 1989-11-13 | 1993-10-12 | Affymax Technologies N.V. | Spatially-addressable immobilization of anti-ligands on surfaces |
EP1231282A3 (en) | 1990-12-06 | 2005-05-18 | Affymetrix, Inc. | Methods and compositions for identification of polymers |
WO1993006121A1 (en) | 1991-09-18 | 1993-04-01 | Affymax Technologies N.V. | Method of synthesizing diverse collections of oligomers |
US5324633A (en) | 1991-11-22 | 1994-06-28 | Affymax Technologies N.V. | Method and apparatus for measuring binding affinity |
US5550215A (en) | 1991-11-22 | 1996-08-27 | Holmes; Christopher P. | Polymer reversal on solid surfaces |
US5384261A (en) | 1991-11-22 | 1995-01-24 | Affymax Technologies N.V. | Very large scale immobilized polymer synthesis using mechanically directed flow paths |
EP0624059A4 (en) | 1991-11-22 | 1994-12-21 | Affymax Technologies N.V. | Combinatorial strategies for polymer synthesis. |
US5491074A (en) | 1993-04-01 | 1996-02-13 | Affymax Technologies Nv | Association peptides |
US5858659A (en) | 1995-11-29 | 1999-01-12 | Affymetrix, Inc. | Polymorphism detection |
US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US5578832A (en) | 1994-09-02 | 1996-11-26 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
US5631734A (en) | 1994-02-10 | 1997-05-20 | Affymetrix, Inc. | Method and apparatus for detection of fluorescently labeled materials |
US6090555A (en) | 1997-12-11 | 2000-07-18 | Affymetrix, Inc. | Scanned image alignment systems and methods |
AU2360195A (en) | 1994-05-05 | 1995-11-29 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
US5571639A (en) | 1994-05-24 | 1996-11-05 | Affymax Technologies N.V. | Computer-aided engineering system for design of sequence arrays and lithographic masks |
US5795716A (en) | 1994-10-21 | 1998-08-18 | Chee; Mark S. | Computer-aided visualization and analysis system for sequence evaluation |
US5599695A (en) | 1995-02-27 | 1997-02-04 | Affymetrix, Inc. | Printing molecular library arrays using deprotection agents solely in the vapor phase |
US5624711A (en) | 1995-04-27 | 1997-04-29 | Affymax Technologies, N.V. | Derivatization of solid supports and methods for oligomer synthesis |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5968740A (en) | 1995-07-24 | 1999-10-19 | Affymetrix, Inc. | Method of Identifying a Base in a Nucleic Acid |
EP0902885A4 (en) | 1996-05-16 | 2006-09-27 | Affymetrix Inc | SYSTEMS AND METHODS FOR DETECTION OF BRANDED PRODUCTS |
EP1027456B1 (en) | 1997-10-31 | 2005-03-16 | Affymetrix, Inc. (a Delaware Corporation) | Expression profiles in adult and fetal organs |
US5936324A (en) | 1998-03-30 | 1999-08-10 | Genetic Microsystems Inc. | Moving magnet scanner |
US6020198A (en) | 1998-09-25 | 2000-02-01 | Isis Pharmaceuticals Inc. | Antisense modulation of RIP-1 expression |
WO2002024956A2 (en) | 2000-09-19 | 2002-03-28 | Whitehead Institute For Biomedical Research | Genetic markers for tumors |
US20030194701A1 (en) | 2000-11-20 | 2003-10-16 | Golub Todd R. | Diffuse large cell lymphoma diagnosis and outcome prediction by expression analysis |
US7473767B2 (en) | 2001-07-03 | 2009-01-06 | The Institute For Systems Biology | Methods for detection and quantification of analytes in complex mixtures |
US7622260B2 (en) | 2001-09-05 | 2009-11-24 | The Brigham And Women's Hospital, Inc. | Diagnostic and prognostic tests |
MXPA04002653A (es) | 2001-09-21 | 2004-07-08 | Boryung Pharm | Metodo para preparar compuestos de pirimidinona y sales farmaceuticamente aceptables del mismo. |
US7371736B2 (en) | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
EP1581629B1 (en) | 2002-12-06 | 2015-04-01 | Millennium Pharmaceuticals, Inc. | Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy |
WO2005016894A1 (en) | 2003-08-15 | 2005-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
US20110152115A1 (en) | 2003-09-03 | 2011-06-23 | The United States of America, as represented by the Secretary, Department of Health and | Methods for identifying, diagnosing, and predicting survival of lymphomas |
JP2007523956A (ja) | 2004-02-25 | 2007-08-23 | ダナ−ファーバー キャンサー インスティテュート インク. | 腫瘍細胞増殖を阻害するための方法 |
EP1805197A1 (en) | 2004-09-27 | 2007-07-11 | Med Biogene Inc | Hematological cancer profiling system |
US8349555B2 (en) | 2005-03-16 | 2013-01-08 | Gennadi V. Glinsky | Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures |
CN101910414B (zh) * | 2007-11-07 | 2016-01-13 | 健泰科生物技术公司 | 用于评估b细胞淋巴瘤对抗cd40抗体治疗的响应性的方法和组合物 |
ES2352777B1 (es) | 2009-07-31 | 2012-01-23 | Hospital Clinic De Barcelona | Metodo y kit para el pronostico del linfoma de celulas del manto |
CA3061784C (en) * | 2009-11-13 | 2023-09-26 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
WO2011097476A1 (en) | 2010-02-04 | 2011-08-11 | Indiana University Research And Technology Corporation | 4-protein biomarker panel for the diagnosis of lymphoma from biospecimen |
US20110293629A1 (en) * | 2010-05-14 | 2011-12-01 | Bastid Jeremy | Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists |
MY191929A (en) * | 2010-06-03 | 2022-07-18 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
EP2601314A4 (en) | 2010-08-04 | 2013-12-11 | Med Biogene Inc | PROGNOSTIC SIGNATURES FOR NON-SMALL LUNG CANCER |
US20140303034A1 (en) | 2011-12-09 | 2014-10-09 | British Columbia Cancer Agency Branch | Predicting prognosis in classic hodgkin lymphoma |
US9803245B2 (en) | 2012-03-14 | 2017-10-31 | University Health Network | Signature for predicting clinical outcome in human HER2+ breast cancer |
US9890430B2 (en) | 2012-06-12 | 2018-02-13 | Washington University | Copy number aberration driven endocrine response gene signature |
WO2014197936A1 (en) | 2013-06-14 | 2014-12-18 | The State Of Queensland Acting Through Its Department Of Health | Biomarkers and use thereof in identification of b-cell lymphoproliferative disorders |
WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
SG11201702895SA (en) | 2014-10-08 | 2017-05-30 | Novartis Ag | Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof |
-
2014
- 2014-11-05 EP EP14803288.1A patent/EP3066215B1/en active Active
- 2014-11-05 WO PCT/US2014/064161 patent/WO2015069790A1/en active Application Filing
- 2014-11-05 JP JP2016553231A patent/JP6657105B2/ja active Active
- 2014-11-05 EP EP19170689.4A patent/EP3594359B1/en active Active
- 2014-11-05 AU AU2014346788A patent/AU2014346788B8/en active Active
- 2014-11-05 ES ES14803288T patent/ES2738289T3/es active Active
- 2014-11-05 CA CA2929826A patent/CA2929826C/en active Active
- 2014-11-05 ES ES19170689T patent/ES2923942T3/es active Active
- 2014-11-05 US US15/035,101 patent/US10607717B2/en active Active
- 2014-11-05 KR KR1020167014876A patent/KR102357699B1/ko active IP Right Grant
- 2014-11-05 CN CN201480072382.7A patent/CN106232831B/zh active Active
-
2020
- 2020-01-17 US US16/746,347 patent/US11574704B2/en active Active
- 2020-02-05 JP JP2020018323A patent/JP7016129B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005024043A2 (en) * | 2003-09-03 | 2005-03-17 | Government Of The United States Of America, As Represented By Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
WO2008013910A2 (en) * | 2006-07-25 | 2008-01-31 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods for identifying, diagnosing, and predicting survival of lymphomas |
JP2011510663A (ja) * | 2008-02-01 | 2011-04-07 | ザ ジェネラル ホスピタル コーポレイション | 医学的疾患および医学的状態の診断、予後および治療におけるマイクロベシクルの使用 |
WO2009149359A2 (en) * | 2008-06-06 | 2009-12-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Survival predictor for diffuse large b cell lymphoma |
JP2012533308A (ja) * | 2009-07-16 | 2012-12-27 | ザ ジェネラル ホスピタル コーポレイション | 核酸分析 |
WO2012149299A2 (en) * | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
WO2013120086A1 (en) * | 2012-02-10 | 2013-08-15 | Whitehead Institute For Biomedical Research | Inhibition of the glycine cleavage system for treatment of cancer |
Non-Patent Citations (2)
Title |
---|
CANCER INFORMATICS, vol. V3, JPN5016011261, 12 December 2007 (2007-12-12), pages 399 - 420, ISSN: 0004186414 * |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. VOL:100, NR:17, JPN5016011262, 19 August 2003 (2003-08-19), pages 9991 - 9996, ISSN: 0003895358 * |
Also Published As
Publication number | Publication date |
---|---|
WO2015069790A1 (en) | 2015-05-14 |
JP6657105B2 (ja) | 2020-03-04 |
WO2015069790A9 (en) | 2016-06-02 |
KR20160127713A (ko) | 2016-11-04 |
CN106232831B (zh) | 2021-02-26 |
JP7016129B2 (ja) | 2022-02-04 |
KR102357699B1 (ko) | 2022-02-04 |
ES2923942T3 (es) | 2022-10-03 |
US20200143906A1 (en) | 2020-05-07 |
EP3594359B1 (en) | 2022-05-18 |
US11574704B2 (en) | 2023-02-07 |
CA2929826C (en) | 2022-08-16 |
EP3594359A1 (en) | 2020-01-15 |
AU2014346788A8 (en) | 2016-06-16 |
EP3066215A1 (en) | 2016-09-14 |
US10607717B2 (en) | 2020-03-31 |
JP2020078323A (ja) | 2020-05-28 |
US20160283653A1 (en) | 2016-09-29 |
EP3066215B1 (en) | 2019-04-24 |
CN106232831A (zh) | 2016-12-14 |
AU2014346788A1 (en) | 2016-05-26 |
ES2738289T3 (es) | 2020-01-21 |
AU2014346788B2 (en) | 2020-09-24 |
AU2014346788B8 (en) | 2021-01-28 |
CA2929826A1 (en) | 2015-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7016129B2 (ja) | 発現プロファイリングによりリンパ腫のタイプをサブタイピングするための方法 | |
JP2018068299A (ja) | 遺伝子発現を用いた前立腺癌の予後を定量化する方法 | |
US20050239079A1 (en) | Predicting outcome with tamoxifen in breast cancer | |
WO2008013910A2 (en) | Methods for identifying, diagnosing, and predicting survival of lymphomas | |
MX2012005822A (es) | Metodos para predecir el desenlace clinico del cancer. | |
WO2005001138A2 (en) | Breast cancer survival and recurrence | |
WO2009156858A1 (en) | Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen | |
AU2017254645B2 (en) | Evaluation of mantle cell lymphoma and methods related thereto | |
WO2020193748A1 (en) | Classification of b-cell non-hodgkin lymphomas | |
EP3638814B1 (en) | Method for determining lymphoma type | |
AU2007277142B2 (en) | Methods for identifying, diagnosing, and predicting survival of lymphomas | |
AU2021291133A1 (en) | Methods for detecting and predicting cancer and/or CIN3 | |
WO2023007165A1 (en) | Methods for assessing epigenetic age and cancer risk | |
Winokur | Molecular markers in breast cancer: current practice and future possibilities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20170224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171102 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171102 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181016 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190315 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191008 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6657105 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |